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Aim:  To quantify  gender,  age-group  and  quantity  of  methadone  prescribed  as risk  factors  for  drugs-related
deaths  (DRDs),  and  for methadone-speciﬁc  DRDs,  in Scotland’s  methadone-prescription  clients.
Design:  Linkage  to  death-records  for  Scotland’s  methadone-clients  with  one  or more  Community  Health
Index  (CHI)-identiﬁed  methadone  prescriptions  during  July  2009  to June  2013.
Setting:  Scotland’s  Prescribing  Information  System  and  National  Records  of Scotland.
Measurements:  Covariates  deﬁned  at  ﬁrst  CHI-identiﬁed  methadone  prescription,  and  person-years  at-
risk (pys)  thereafter  until  the earlier  of  death-date  or 31  December  2013.  Methadone-speciﬁc  DRDs
were  deﬁned  as:  methadone  implicated  but neither  heroin  nor  buprenorphine.  Hazard  ratios  (HRs)  were
assessed  using  proportional  hazards  regression.
Findings:  Scotland’s  CHI-identiﬁed  methadone-prescription  cohort  comprised  33,128  clients,  121,254
pys,  1,171  non-DRDs  and  760  DRDs (6.3  per  1,000  pys),  of  which  362  were  methadone-speciﬁc.  Irrespec-
tive  of gender,  methadone-speciﬁc  DRD-rate,  per 1,000  pys,  was  higher  in  the  35+ age-group  (4.2;  95%
CI:  3.6–4.7)  than  for younger  clients  (1.9; 95% CI: 1.5–2.2).  For  methadone-speciﬁc  DRDs, age-related  HRs
(e.g.,  2.9  at  45+  years;  95%  CI:  2.1–3.9)  were steeper  than  for all  DRDs  (1.9; 95%  CI:  1.5–2.4);  there  was  no
hazard-reduction  for females;  no  gender  by age-group  interaction;  and,  unlike  for all  DRDs, the  highest
quintile  for  quantity  of prescribed  methadone  at cohort-entry  (>1960  mg)  was  associated  with  increased
HR  (1.8;  95%  CI:  1.3–2.5).
Conclusion: Higher  methadone-speciﬁc  DRD  rates  in  older  clients,  irrespective  of  gender, call  for  bet-
ter  understanding  of  methadone’s  pharmaco-dynamics  in older,  opioid-dependent  clients,  many  with
progressive  physical  or mental  ill-health.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
Despite other options (buprenorphine, morphine, heroin)
ethadone, prescribed as a 1 mg/1 ml  solution, is the major con-
ributor to opioid substitution therapy (OST) globally and accounts
or the vast majority of Scotland’s OST over the past 30 years
World Health Organization, 2009; Department of Health et al.,
999, 2007; National Institute for Health and Clinical Excellence,
007; Information Services Division and Scotland, 2015). With a
∗ Corresponding author at: MRC  Biostatistics Unit, Cambridge, CB2 0SR, United
ingdom.
E-mail address: sheila.bird@mrc-bsu.cam.ac.uk (S.M. Bird).
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.08.627
376-8716/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
population of 5.2 million, including 60,000 problem drug users,
Scotland dispensed around 600,000 L of methadone per annum
from 2009 to 2013. The Scottish Drug Strategy Delivery Commission
(2013), tasked by Scottish Ministers to conduct an independent
review of Scotland’s OST, endorsed the professional standards
(including supervision) by which opioid dependency was  man-
aged in Scotland and also the value of methadone as a treatment
which halves clients’ risks of drugs-related death (DRD) and
reduces blood-borne viruses and criminality (Strang et al., 2010;
Degenhardt et al., 2011; White et al., 2015; Pierce et al., 2016,
2015b).
Over the past decade, different study methods in different juris-
dictions have persuaded the addiction community that there is
a strong empirical interaction between gender and age-group in
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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RD-rates, whereby female opioid users’ experience a much lower
RD-rate than their male counterparts at younger ages but, pro-
ressively, this advantage weakens beyond 35 years of age. We
onjectured that the prescribing of methadone could be implicated
n this gender by age-group interaction.
Methadone prescribing was under scrutiny in Scotland because
RDs in which methadone was implicated were increasing, even
llowing for the quantity prescribed (as proposed by Strang et al.,
010) and because only a minimum estimate for Scotland’s num-
er of methadone-clients could be given (The Scottish Government,
008; HM Government, 2010; Ferguson, 2012; Scottish Public
ealth Observatory, 2015): latterly, those identiﬁable by their Com-
unity Health Index (CHI) number (Ellison, 2015). A CHI-number
s uniquely assigned to patients in Scotland’s National Health
ervice (NHS) and used as a basis for efﬁcient, trusted record-
inkage (Pavis and Morris, 2015). However, the availability of the
HI-number on methadone prescriptions varies by prescription-
ource (Dimitropoulou et al., 2016; Alvarez-Madrazo et al., 2016),
eing higher for prescriptions issued by general practitioners (GPs)
han for other-source prescriptions which are used by commu-
ity drug services. Using CHI-numbers and plausible assumptions,
imitropoulou et al. (2016) developed an upper bound for Scot-
and’s number of methadone-clients: from July 2012 to June 2013
hereafter 2012/13), 16,900 to 19,600 were managed by Scotland’s
Ps but the totality of methadone-clients was 25,100 to 36,500.
reater precision was possible for GP-clients because, by 2012/13,
he majority (86%) of methadone prescriptions by GPs had the
lient’s CHI-number in contrast to 47% for other-source prescrip-
ions.
Questions were raised, and continue to be in the media
Ferguson, 2012; Ellison, 2015), about the persistence of Scotland’s
ethadone clients across prescription-years, which was substan-
ial during 2009/10 to 2012/13 (see Supplementary material.1).
People on longer-term methadone maintenance are, of course,
geing and their DRD-rate rises accordingly (Pierce et al., 2016;
errall et al., 2012; Pierce et al., 2015a; King et al., 2013, 2014;
ousins et al., 2011; Cornish et al., 2010; Bird et al., 2010).
We hypothesised that possible reasons for OST clients’ increas-
ng DRD-rate with age included the methadone prescribed to
lder clients (Dimitropoulou et al., 2016), as directly implicated or
ndirectly through co-morbidities. Electrocardiograms are recom-
ended for older or persistent methadone clients on higher doses
Medicines and Healthcare products Regulatory Agency (MHRA),
006) to detect QTc prolongation (see Discussion section, below),
or which being female (Makkar et al., 1993; Kest et al., 2000; Lee
nd Ho, 2013; Graziani and Nistico, 2015; Bawor et al., 2014), co-
orbidities and co-prescribing are also risk factors.
As access to OST has expanded, the opioid-speciﬁcity of DRDs in
cotland, as elsewhere, has changed (Strang et al., 2010; Zador and
unjic, 2002; Seymour et al., 2003; McCowan et al., 2009; Bird and
obertson, 2011; Pilgrim et al., 2013; Bernard et al., 2013; Cousins
t al., 2016; Winker et al., 2014; Kimber et al., 2015). National
ecords of Scotland (NRS, 2015) now publishes, as ofﬁcial statis-
ics, Scotland’s number of opioid-related deaths cross-tabulated by
ender and age-group. Co-presence of benzodiazepines or alcohol
t DRDs has been remarked upon (Seymour et al., 2003; McCowan
t al., 2009; Bird and Robertson, 2011; Christie, 2011; Leece et al.,
015; Park et al., 2015) but, whereas diazepam was  present at 70%
f Scotland’s DRDs in 2013 or 2014, diazepam was implicated in
nly 14% of Scotland’s DRDs; and, when present, was prescribed in
he past 30 days for only one in six DRDs (Barnsdale et al., 2015,
016) and so was mainly illicitly acquired.
1 Supplementary material can be found by accessing the online version of this
aper at http://dx.doi.org and by entering doi:. . .ndence 167 (2016) 214–223 215
The recent rise in Scotland’s methadone-implicated DRDs, and
likewise in England (White and Hamilton, 2016), re-ignited concern
about long-term treatment with methadone or its possible diver-
sion. Scotland’s National Drugs-Related Death Database (Barnsdale
et al., 2015) reported that methadone was  not prescribed at the
time of death in 2013 for 41% of those in whose DRD methadone
was implicated. Too low a daily-dose of methadone, of course, com-
promises retention in OST (Kimber et al., 2010) and, since being
off-OST doubles clients’ DRD-risk, the public health challenge in
2016, as in 1999 (Ward et al., 1999), is to deliver safe and effective
forms of OST for as long and to as many ageing opioid-dependent
individuals as can beneﬁt (Department of Health et al., 2007).
Hence, in this paper, our aims were:
1 To document DRD-rates and methadone-speciﬁc DRD  rates by
gender and age-group for Scotland’s cohort of CHI-identiﬁed
methadone clients between July 2009 and June 2013;
2 To apply proportional hazards regression to analyse risk factors at
cohort-accrual (including quintile for the quantity of prescribed
methadone) for methadone-speciﬁc DRDs; and for all DRDs.
2. Methods
2.1. Drug related deaths
We used the UK harmonized deﬁnition of DRD (National Records
of Scotland, 2015) and requested information on the opioid-
speciﬁcity of Scotland’s DRDs from NRS as follows:
i) Methadone-speciﬁc DRDs: methadone was implicated in DRD,
but neither heroin nor buprenorphine was implicated,
ii) Heroin-speciﬁc DRDs: heroin was  implicated in DRD, but nei-
ther methadone nor buprenorphine was implicated,
iii) DRDs in which methadone and heroin were both implicated,
but buprenorphine was not.
In appraising which drugs are implicated as causal factors in
any DRD and which, although present, probably did not contribute,
Scotland’s pathologists are supported by having a national protocol
for toxicological testing at forensic autopsies.
2.2. Scotland’s community health index and CHI-number
The CHI is a register of all patients in Scotland’s publicly funded
healthcare system, NHS Scotland. Patients are identiﬁed by a 10-
digit CHI-number, usually the patient’s date of birth (DDMMYY)
followed by four digits: two  randomly generated, the third identi-
fying gender (odd for males) and the fourth a check digit (see Pavis
and Morris (2015) on the criticality of CHI-numbers for Scotland’s
efﬁcient, trusted record-linkage).
2.3. Record-linkage for Scotland’s methadone-client cohort
To assess explanatory factors for methadone-speciﬁc DRDs
among those who  had been prescribed methadone in Scotland in
2009–2013, we needed to link methadone-prescriptions to NRS’s
mortality records. Because all deaths are CHI-identiﬁed, Scot-
land’s CHI-number was used for this exact record-linkage. We
deﬁned Scotland’s methadone-prescription cohort as: clients who
had received one or more CHI-identiﬁed methadone prescriptions
(from GP or other-source) during 1 July, 2009–30 June 2013. In
the Results section, below, we  report the percentage of methadone
prescriptions that were CHI-identiﬁed (63%) and the higher esti-
mated percentage of methadone clients (82%) with at least one
CHI-identiﬁed prescription.
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The cohort was followed-up for mortality until 31 December
013. Time at risk began at the date of the client’s ﬁrst CHI-
dentiﬁed prescription during 1 July, 2009–30 June 2013 and ended
t the earlier of death-date or 31 December 2013. The research-ﬁle
as prepared in October 2014. As the requested date of the ﬁrst
HI-identiﬁed prescription was missing for 61% of clients, the date
f its re-imbursement was substituted. When both dates were pro-
ided, the re-imbursement date was, on average, 37 days later (sd
9 days).
Unlike in England and Wales, death registrations in Scotland
ccur within eight days of death having been ascertained (Bird,
013, 2016); and NRS publishes ofﬁcial statistics on DRDs that
ccurred in year y in mid-August of the following year (y + 1).
Our record-linkage protocol was approved by Scotland’s Pri-
acy Access Committee. To preserve client conﬁdentiality, all
HI-identiﬁed methadone-prescriptions and death-records were
seudonymized in a manner which enabled the research team
o link CHI-identiﬁed prescriptions and death-information for the
ame client.
.4. Methadone-prescriptions
Methadone-prescriptions were accessed from Scotland’s Pre-
cribing Information System (Alvarez-Madrazo et al., 2016) which
ontains information on all prescriptions written in Scotland and
ispensed in the community. Only CHI-identiﬁed methadone-
rescriptions for the same individual were linkable. The CHI-rate
or methadone-prescriptions differed by year (higher in 2012/13
han in 2009/10) and prescription-source (higher for GPs than
ther-source prescriptions; see Dimitropoulou et al., 2016).
The quantity of methadone prescribed was always available as
harmacies are re-imbursed for the quantity prescribed. Duration
f methadone-prescription and daily-dose could only be derived
or GP prescriptions which had used an electronic dose instruc-
ion message. Natural language programming was  applied to the
ree-text of this electronic message to abstract daily-dose (see
imitropoulou et al. (2016) for the programme details). Extraction-
ates for daily-dose of prescribed methadone were 79.3% from
40,361 electronic dose instruction GP-prescriptions in 2009/10
nd 94.4% for 133,386 GP-prescriptions in 2012/13 (Dimitropoulou
t al., 2016).
.5. Statistical methods
Time at risk in days was converted to person-years (pys) by
ividing the number of days at risk by 365.25 days. If prescription-
ate was missing, the later re-imbursement date was substituted
see above), which accounted for some negative time-intervals
rom the ﬁrst CHI-identiﬁed prescription-date to death-date. With-
ut loss of generality, we  added 60 days to all times at risk and so
tted proportional hazards regression models to the time-at-risk
lus 60 days, which avoided almost all negative times as the 90th
ercentile for the known re-imbursement delays was  60 days.
Only baseline covariates (that is: not time-varying, see below
or reasons) were assessed, namely: those deﬁned by the client’s
rst CHI-identiﬁed methadone-prescription between July 2009 and
une 2013. Baseline covariates were prescription-source (GP vs.
ther-source); gender, age-group and their interaction; quintiles
or the quantity of methadone prescribed; plus regions with his-
orically high prevalence of heroin injecting (Greater Glasgow and
lyde, Lothian, Tayside, versus rest of Scotland) as a potential con-
ounder.Our reasons for not updating the quantity of methadone pre-
cribed were three-fold: death informatively censors subsequent
ethadone-prescriptions; follow-up continued for six-months
eyond the four years for accrual of CHI-identiﬁed methadone-ndence 167 (2016) 214–223
prescriptions; and a client’s later methadone-prescriptions, even
within the four years, need not be CHI-identiﬁed. Hence, the date
of a client’s last CHI-identiﬁed methadone-prescription prior to 30
June 2013 does not necessarily indicate the date when methadone-
prescribing ceased. By investigating accrual covariates only, which
all clients have by deﬁnition, we  introduced neither informative
censoring nor ascertainment bias.
We  investigated inﬂuential baseline covariates for methadone-
speciﬁc DRDs, our focal interest; and for all DRDs, as the
conventional analysis. As a sensitivity check, we analysed
methadone-speciﬁc DRDs separately for clients accrued in 2009
(mostly prevalent) versus later (mostly incident).
For the subset of GP-clients for whom daily-dose of methadone
at the ﬁrst CHI-identiﬁed prescription was known, we  also investi-
gated quintiles for daily-dose of prescribed methadone.
We used STATA 12.1 for analysis. We  present 95% conﬁdence
intervals for deaths per 1000 pys; and for hazard ratios (HRs).
3. Results
During 2009/10 to 2012/13, Scotland had 2,030,457 methadone
prescriptions, 1,282,555 (63%) of which were CHI-identiﬁed. The
CHI-identiﬁed prescriptions related to 33,128 methadone clients,
82% of Scotland’s 40,606 methadone clients during 2009/10 to
2012/13, as best-estimated using the method of Dimitropoulou
et al. (2016).
The majority (63%, 20,758 clients) joined the cohort in July
to December 2009, mostly prevalent clients. During follow-up of
121 254 pys to 31 December 2013, there were 1931 deaths. The
cohort experienced 1171 non-DRDs and 760 DRDs at rates of 9.7
non-DRDs (95% CI: 9.1–10.2) and 6.3 DRDs (95% CIs: 5.8–6.7) per
1000 pys respectively. Buprenorphine was implicated in only seven
DRDs and there were 67 DRDs in which none of heroin/morphine,
methadone, or buprenorphine was implicated.
3.1. Demographic and other risk-factors
Methadone-speciﬁc DRDs (362) were more than double the
cohort’s number of heroin-speciﬁc DRDs (173) or DRDs in which
both heroin and methadone but not buprenorphine were impli-
cated (151), see Table 1.
Opioid-speciﬁcity of clients’ DRDs varied by prescription-
source, gender and age-group at cohort-entry. [The non-DRD:
DRD ratio also varied by covariates, for example: higher for GP-
prescribers and older clients.]
Clients whose ﬁrst CHI-identiﬁed methadone-prescription was
other-source had a higher methadone-speciﬁc DRD-rate. By gen-
der, the male heroin-speciﬁc DRD-rate was signiﬁcantly higher at
1.8 per 1,000 pys (5% CI: 1.4–2.0) than for females (0.8, 95% CI:
0.5–1.1) but clients’ methadone-speciﬁc DRD-rate was 3.0 irrespec-
tive of gender.
Clients whose age at ﬁrst CHI-identiﬁed prescription in
2009–2013 was  35+ years had a DRD-rate of 7.7 (95% CI: 7.0–8.4)
versus 4.9 (95% CI: 4.4–5.5) per 1,000 pys for younger clients. In par-
ticular, methadone-speciﬁc DRD-rates were substantially higher in
the older age-group than for younger clients: 4.2 (95% CI: 3.6–4.7)
versus 1.9 (95% CI: 1.5–2.2) per 1,000 pys.
For older clients, neither the DRD-rate nor the methadone-
speciﬁc DRD-rate was  lower for females. By contrast, in the younger
age-group, the DRD-rate was  higher for males than females, see
Table 1: interaction.Regional variation in the methadone-speciﬁc DRD-rates was
unremarkable (chi-square on 3df of 5.78, p = 0.12). However, Tay-
side’s signiﬁcantly high DRD-rate could be a confounder when
analysing DRDs.
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Table  1
For major sub-groups, numbers of deaths by deﬁned opioid-speciﬁcity and person-years (pys) at risk since ﬁrst CHI-identiﬁed prescription to earlier of death-date or 31
December 2013.
Sub-group deﬁned by 1st
CHI-identiﬁed prescription
Clients Non-DRDs DRDs Opioid-speciﬁc DRD sub-groups Person-years, pys
Heroin: yes Heroin: no Heroin: yes
Meth: no Meth: yes Meth: yes
Bupren: no Bupren: no Bupren: no
Scotland-wide 33 128 1171 760 173 362 151 121 254 pys
Death-rate per 9.7 6.3 1.4 3.0 1.2
1000  pys (95% CI) (9.1–10.2) (5.8–6.7) (1.2–1.6) (2.7–3.3) (1.0–1.4)
Prescription source
GP-prescription 22 114 887 502 130 232 86 84 338 pys
Death-rate per 10.5 6.0 1.5 2.8 1.0
1000  pys (95% CI) (9.8–11.2) (5.4–6.5) (1.3–1.8) (2.4–3.1) (0.8–1.2)
Other-source 11 014 284 258 43 130 65 36 916 pys
Death-rate per 7.7 7.0 1.2 3.5 1.8
1000  pys (95% CI) (6.8–8.6) (6.1–7.8) (0.8–1.5) (2.9–4.1) (1.3–2.2)
Gender
Males 22 025 827 535 141 240 108 80 394 pys
Death-rate per 10.3 6.7 1.8 3.0 1.3
1000  pys (95% CI) (9.6–11.0) (6.1–7.2) (1.4–2.0) (2.6–3.4) (1.1–1.6)
Females 11 103 344 225 32 122 43 40 860 pys
Death-rate per 8.4 5.5 0.8 3.0 1.1
1000  pys (95% CI) (7.5–9.3) (4.8–6.2) (0.5–1.1) (2.4–3.5) (2.4–3.5)
Age-group at Cohort-Entry
35+  years @ Cohort-entry 16 002 886 451 78 244 86 58 462 pys
Death-rate per 15.2 7.7 1.3 4.2 1.5
1000  pys (95% CI) (14.2–16.2) (7.0–8.4) (1.0–1.6) (3.6–4.7) (1.2–1.8)
<  35 years @ Cohort-entry 17 126 285 309 95 118 65 62 792 pys
Death-rate per 4.5 4.9 1.5 1.9 1.0
1000  pys (95% CI) (4.0–5.1) (4.4–5.5) (1.2–1.8) (1.5–2.2) (0.8–1.3)
Gender by Age-group at Cohort-Entry: interaction
Male,  35+ 11 540 632 320 68 163 63 42 126 pys
Death-rate per 15.0 7.6 1.6 3.9 1.5
1000  pys (95% CI) (13.8–16.2) (6.8–8.4) (1.2–2.0) (3.3–4.5) (1.1–1.9)
Female, 35+ 4 462 254 131 10 81 23 16 336 pys
Death-rate per 15.5 8.0 0.6 5.0 1.4
1000  pys (95% CI) (13.6–17.5) (6.6–9.4) (0.3–1.1) (3.9–6.0) (0.9–2.1)
Male,  < 35 10 485 195 215 73 77 45 38 268 pys
Death-rate per 5.1 5.6 1.9 2.0 1.0
1000  pys (95% CI) (4.4–5.8) (4.8–6.4) (1.5–2.4) (1.5–2.5) (0.8–1.5)
Female, < 35 6 641 90 94 22 41 20 24 524 pys
Death-rate per 3.7 3.8 0.9 1.7 0.8
1000  pys (95% CI) (2.9–4.4) (3.1–4.6) (0.5–1.4) (1.1–2.2) (0.5–1.3)
Region at cohort entry
G.  Glasgow & Clyde 12 261 525 307 82 135 56 47 465 pys
Death-rate per 11.1 6.5 1.7 2.8 1.2
1000  pys (95% CI) (10.2–12.0) (5.8–7.2) (1.4–2.1) (2.6–4.3) (0.9–1.5)
Lothian 4 801 170 84 10 58 11 17 423 pys
Death-rate per 9.8 4.8 0.6 3.3 0.6
1000  pys (95% CI) (8.4–11.3) (3.9–6.0) (0.3–1.1) (2.5–4.2) (0.4–1.1)
Tayside 2 760 87 74 7 34 23 8 034 pys
Death-rate per 10.8 9.2 0.9 4.2 2.9
1000  pys (95% CI) (8.8–13.4) (7.3–11.6) (0.4–1.8) (3.0–5.9) (1.9–4.3)
Rest  of Scotland 13 306 389 295 74 135 61 48 335 pys
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.2. Proportional hazards analyses
Only four time-intervals remained negative after the universal
ddition of 60 days (see Methods section) and so, without loss of
enerality, these few clients were excluded from regression analy-
es. Two were DRDs, one of them methadone-speciﬁc.
Quintiles for the quantity of methadone prescribed at ﬁrst
HI-identiﬁed prescription were as follows: < = 280; 281–700;
01–1200; 1201–1960; and >1960 mg.  As shown in Supplementary
aterial2, quintiles for daily dose of prescribed methadone in the
2 Supplementary material can be found by accessing the online version of this
aper at http://dx.doi.org and by entering doi:. . .1.5 2.8 1.3
(1.2–1.9) (2.4–3.3) (1.0–1.6)
GP-subset with e-readable dose instructions were: < = 30; 31–50;
51–70; 71–90; and >90 mg.
With neither region nor gender by age-group interaction ﬁtted
and irrespective of whether quintiles were ﬁtted, clients’ age-
related HRs were steeper for methadone-speciﬁc DRDs (Table 2,
top panel) than for all DRDs (Table 3, top panel): for example, HRs
of 1.9 and 2.9 for the two oldest age-group in Table 2 versus 1.4
and 1.9 in Table 3. The highest quintile for quantity of prescribed
methadone was associated with a HR for 1.8 (95% CI: 1.3–2.5) for
methadone-speciﬁc DRDs but not for all DRDs.The lower panel of Table 3 conﬁrmed the familiar gender by age-
group interaction for DRD-hazards, and showed that confounding
by region was largely responsible for the apparently higher DRD-
hazard in Table 1 for other-source prescriptions.
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Table  2
Proportional hazards analysis from ﬁrst CHI-identiﬁed prescription to methadone-speciﬁc DRDs: with adjustment for baseline covariates excluding or including quintiles
for  prescribed quantity of methadone.
Covariates
361 Methadone-speciﬁc DRDs; 33,124 at-risk clients
Regression chi-square test on 3df for interaction (gender*age-group)
when region also ﬁtted = 3.30, p ∼0.35
Excluding QUINTILES for
prescribed quantity
Including QUINTILES for
prescribed quantity
Regression chi-square (9 df) = 98.88
HR 95% CI p-value HR 95% CI p-value
No interaction needed for gender * age-group
Regression chi-square (4df) for QUINTILES 22.98, p ∼0.0001
Other-source 1.42 1.15–1.77 0.001 1.44 1.16–1.79 0.001
Female 1.12 0.90–−1.39 0.322 1.14 0.91–1.42 0.246
AGE-GROUP with 25–34 years at ﬁrst CHI-identiﬁed prescription as baseline
Age < 25 0.51 0.26–1.00 0.050 0.53 0.27–1.04 0.064
Age  35–44 1.95 1.53–2.48 <0.001 1.91 1.50–2.44 <0.001
Aged  45+ 2.95 2.18–4.00 <0.001 2.90 2.14–3.93 <0.001
QUINTILES for prescribed quantity of methadone with lowest quintile as baseline
Quintile 2: 281–700 1.10 0.76–1.59 0.604
Quintile 3: 701–1200 0.90 0.61–1.32 0.577
Quintile 4: 1201–1960 1.22 0.86–1.74 0.261
Quintile 5: > 1960 mg(For example, 1960 mg  = 14 days@140 mg  daily or28 days @ 70 mg) 1.79 1.29–2.50 <0.001
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regression chi-square (on 3df) for REGION was statistically signiﬁcant, see below
Regression chi-square (3df) for REGION 
There was no female advantage when it came to methadone-
peciﬁc DRDs, nor regional differences (unlike for all DRDs). For
lients whose ﬁrst CHI-identiﬁed prescription was  other-source,
he HR for methadone-speciﬁc DRDs was 1.4 (95% CI: 1.2–1.8).
For mostly prevalent clients (those recruited in July to December
009), the quantity of prescribed methadone at cohort-entry was
ikely to represent the clients’ typical or stabilized prescription
ut, for mostly incident clients (those recruited after 2009, for 34%
f whom the quantity of prescribed methadone was  in the low-
st quintile), quantity prescribed at cohort-entry was  more likely
o represent initial prescribing. See Supplementary material3 for
H analysis of methadone-speciﬁc DRDs separately for clients who
ccrued in July to December 2009 (mostly prevalent) versus later.
he stratiﬁcation was highly signiﬁcant (chi-square test on 9 df of
8.21, p ∼0.0009) with four main points of difference. Other-source
rescribing applied for half the mostly incident clients (versus
nly 22% of 2009-accrued clients) and, for them, was  associated
ith a signiﬁcantly greater hazard of methadone-speciﬁc DRD (test
or interaction: p ∼0.05). For clients aged 45+ years, the HR for
ethadone-speciﬁc DRD was more extreme for mostly incident
han mostly prevalent clients. Thirdly, clients who entered the
ohort after 2009 with a baseline quantity of prescribed methadone
f 281–700 mg  were at relatively greater risk of methadone-speciﬁc
RD than their mainly prevalent counterparts. Fourth, the highest
uintile for quantity of prescribed methadone applied to only 13%
f mostly incident clients but was associated with a notably high
R of 2.8 (95% CI: 1.5–5.1) for methadone-speciﬁc DRD.
For the GP-subset of clients with known daily-dose at their ﬁrst
HI-identiﬁed prescription, the highest quintile for daily-dose of
rescribed methadone (>90 mg)  may  be even more prognostic than
or quantity prescribed, see Supplementary material43 Supplementary material can be found by accessing the online version of this
aper at http://dx.doi.org and by entering doi:. . .
4 Supplementary material can be found by accessing the online version of this
aper at http://dx.doi.org and by entering doi:. . .ayside, rest of Scotland] were added to the above models, neither
5.80, p ∼0.12 2.42, p ∼0.49
4. Discussion
4.1. Summary of main ﬁndings
Scotland’s methadone-prescription cohort reveals for the ﬁrst
time that clients’ age-related hazard increases more steeply for
methadone-speciﬁc DRDs than for all DRDs (e.g.,HR for males aged
45+ years: 2.9 versus 1.9). Although Pierce et al. (2015a, 2016)
showed that DRD-rates increased beyond 45 years of age for Eng-
land’s drug treatment clients, they did not have information on
the opioid-speciﬁcity of DRDs to enable an analysis of methadone-
speciﬁc DRDs. Nor did they have information on the quantity of
prescribed methadone. Importantly, the steeply age-related HRs
for methadone-speciﬁc DRDs in Scotland’s methadone client cohort
were evident in Table 2, even without ﬁtting quintiles for the quan-
tity of methadone and so validation studies in other OST cohorts,
which are necessary, can proceed primarily by ascertaining the
opioid-speciﬁcity of their DRDs.
Unlike for all DRDs, there was no overall hazard-reduction for
females in respect of methadone-speciﬁc DRDs; no gender by age-
group interaction, see Table 1; and consistent with the Scottish
Drug Strategy Delivery Commission’s endorsement of the pro-
fessional standards by which OST was delivered in Scotland, no
regional variation. For methadone-speciﬁc DRDs, but not all DRDs,
the highest quintile for quantity of prescribed methadone was asso-
ciated with signiﬁcantly increased hazard (1.8; 95% CI: 1.3–2.5).
4.2. Key considerations
Unlike buprenorphine, methadone − alone and with other
drugs commonly used for mental health conditions (see Medicines
and Healthcare products Regulatoy Agency (MHRA), 2006) and
NHS Greater Glasgow and Clyde Medicines Information Service,
2012)—is known to affect the electrical conductivity of the heart
muscle. Speciﬁcally, prolongation of part of the normal electrical
cycle, known as the QT interval, and measurable by an electro-
cardiogram (ECG), can occur (Wedman et al., 2007; Kornick et al.,
2003; Peles et al., 2007; Weimer and Chou, 2014; Chou et al.,
2014a, 2014b; Bohnert et al., 2001; Gomes et al., 2011; Liang and
Yurner, 2015). Prolongation of the corrected QT interval (cQT) and
its sequelae of torsades de pointes has been associated with the
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isk of sudden cardiac death (Maremmani et al., 2005; Roden,
006; Justo et al., 2006; Fanoe et al., 2007; Chugh et al., 2008).
hether undiagnosed QTc prolongation contributes to the tally
f methadone-speciﬁc DRDs is unknowable because prolongation
eaves no detectable trace at autopsy (Chugh et al., 2008). Other risk
actors for QTc prolongation include co-morbidities such as renal
mpairment, heart or liver disease; and being female (Makkar et al.,
993; Kest et al., 2000; Lee and Ho, 2013; Graziani and Nistico,
015; Bawor et al., 2014).
In 2006, MHRA recommended that any patient requiring morehan 100 mg  of methadone per day should be closely monitored.
eriodic heart monitoring of methadone clients has been recom-
ended to detect QTc prolongation by 60 milliseconds or to above
00 milliseconds, but evidence on the effectiveness of such screen-
able 3
roportional hazards analysis from ﬁrst CHI-identiﬁed prescription to DRD: with adjustm
f  methadone.
Covar iates
(nu mber of cli ents )
758  Drug-Related Deaths; 33 ,124  at-risk c
Exclud ing QUINTILES for 
prescribed qu anty
Includ ing QUIN
prescribed q 
HR 95% CI p-value HR 95% C
No interacon
Regression chi-squar e (4df)  for  QUINTILES 19.95 , p ~ 0.000
Other-source 1.27 1.09-1.48 0.002 1.30 1.12-1.
Female 0.88 0.75-1.03 0.118 0.88 0.75-1.
AGE-GROUP with 25-34 years at ﬁrst CHI-idenﬁed prescripon as baselin
Age < 25 ( 2 50 9) 0.70 0.48-1.02 0.062 0.69 0.47-1.
Age 35-44 (12 377) 1.40 1.20-1.65 <0.001 1.42 1.20-1.
Aged 45+ ( 3 62 2) 1.90 1.53-2.36 <0.00 1 1.91 1.54-2.
QUINTILES for prescribed quanty of methadone with lowest quinle as baseline
Quinle 2:   281- 700 1.14 0.91-1.
Quinle 3:   701- 1200 0.74 0.58-0.
Quinle 4: 120 1- 196 0 0.86 0.68-1.
Quinle 5: > 1960mg
(For example, 196 0mg =
14 days@140mg daily or 
28 day s @ 70 mg)
1.02 0.82-1.
Includ ing REGION and  Interacon for gender * age-group
Regression chi-squar e (4df)  for  QUINTILES 17.18 , p ~ 0.00 18
Other-source 1.15 0.96-1.38 0.12 8 1.17 0.97-1.
Female 0.74 0.57-0.96 0.02 2 0.74 0.57-0.
AGE-GR OUP with 25-34  years at ﬁrs t CHI-idenﬁed prescripon as  bas eli n
Age < 25 0.92 0.58-1.46 0.726 0.91 0.57-1.
Age 35-44 1.27 1.05-1.53 0.01 5 1.28 1.06-1.
Aged 45 + 1.67 1.29-2.16 <0.00 1 1.68 1.29-2.
Female age <25 (1 35 9) 0.53 0.24-1.18 0.121 0.54 0.24-1.
Female, 35-44 (3 438) 1.39 0.98-1.97 0.064 1.39 0.98-1.
Female age 45+ (1 024) 1.53 0.96-2.44 0.077 1.52 0.95-2.ndence 167 (2016) 214–223 219
ing is weak (Pani et al., 2013): with detection in perhaps 2% of
clients and mostly on doses greater than 100 mg daily. The quan-
tity of prescribed methadone was >1960 mg  for a ﬁfth of Scotland’s
methadone-prescription clients (and >90 mg daily for 18% of the
GP subset) and so we  speculate that the ECG-detection rate for QTc
prolongation could between 5% and 10% for Scotland’s methadone-
prescription clients in the top quintile of prescribed methadone.
Moreover, ECGs on a representative sample of only 200 clients from
the top quintile, if they were willing to attend for screening, could
estimate the detection-rate for QTc prolongation rather well: with
a standard error of about 2%. However, the clear HR warning in
Table 2 is that precautionary monitoring, including by ECG, may  be
warranted for all methadone clients over 45 years of age.
ent for baseline covariates excluding or including quintiles for prescribed quantity
li ents
TILES for 
uanty
I p-value
5
52 0.001
03 0.12 3
e
00 0.05 3
66 <0.001
38 <0.00 1
42 0.255
95 0.017
09 0.206
28 0.841
41 0.09 1
96 0.02 3
e
44 0.67 6
55 0.01 2
17 <0.00 1
19 0.12 6
97 0.065
43 0.078
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Table  3 (Continued)
QUINTILES for prescri bed qu anty of methad one with lowest qu inle as baseline
Quinle 2:   281- 700 1.15 0.92-1.43 0.23 1
Quinle 3:   701- 1200 0.74 0.58-0.95 0.01 9
Quinle 4: 120 1- 196 0 0.85 0.67-1.07 0.16 3
Quinle 5: > 1960  mg
(For example, 196 0mg =
14 days@14 0mg daily or  
28 day s @ 70 mg) 
1.05 0.84-1.32 0.68 2
REGION with Gr eater Glas gow & Cl yde as  bas eli ne
Lothian 0.79 0.62-1.00 0.05 5 0.77 0.60-0.98 0.03 7
Tayside 1.47 1.09-1.96 0.01 0 1.49 1.11-2.00 0.00 8
Rest of Scotland 0.97 0.81-1.16 0.73 6 0.97 0.82-1.16 0.78 0
Regression  chi-squar e 13.11 , p ~ 0.00 44 14.51 , p ~ 0.00 23
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In view of the above risk-factors for QTc prolongation, future
ecord-linkage for Scotland’s CHI-identiﬁed methadone clients will
eek to link-in not only clients’ diagnoses for blood-borne viruses
Hepatitis B, C and HIV) but also cardiac, gastro-intestinal, alcohol-
elated (Hutchinson et al., 2005; McDonald et al., 2008, 2010) and
ental-health hospitalizations to try to unravel contributory fac-
ors to methadone-speciﬁc DRDs’ strong age-gradient and absent
ender effect. Co-prescription of benzodiazepines is likely to be
f little help, however, as illicit access predominates at DRDs
Barnsdale et al., 2015, 2016). Self-reported misuse of benzodi-
zepines has, however, been shown to increase DRD-risk (Pierce
t al., 2016).
The quantity of methadone prescribed at cohort-entry was
vailable for all clients. Quantity prescribed played a key role
n clients’ risk of methadone-speciﬁc DRD, but not for all DRDs.
or the GP subset, daily-dose of prescribed methadone (>90 mg)
nderlined the association. Despite inevitable uncertainties about
ausation (Hill, 1965), the novel ﬁndings from Scotland—a ﬁrst
nd so requiring external corroboration—serve to emphasise 21st
entury alerts to prescribers and their opioid-dependent clients,
specially new clients, to be cautious if either the quantity of
ethadone prescribed exceeds 1,960 mg  (for example: 140 mg  for
4 days; or, typically, over 90 mg  daily for 28 days but dispensed
n 21 instalments, see Supplementary material5); or daily-dose
xceeds 90 mg.  Similar warnings about daily-dose in excess of
00 mg  have been enunciated for patients receiving methadone
or non-cancer pain (Chou et al., 2014a, 2014b) who, for the most
art, would not have progressive liver disease (Gibson et al., 2011;
ierce et al., 2015a) or other co-morbidities. Co-morbidities clearly
ffect Scotland’s ageing methadone clients (Hutchinson et al., 2005;
cDonald et al., 2008, 2010; Kimber et al., 2010; Merrall et al.,
012). The Scottish data suggests that prescribers may  need to dis-
uss risk-mitigation with all methadone clients over 45 years of
ge.
We found an increased adjusted hazard of methadone-speciﬁc
RD for other-source prescribers, more particularly for incident
lients. A contributory factor here could be that the physical and
5 Supplementary material can be found by accessing the online version of this
aper at http://dx.doi.org and by entering doi:. . .psychiatric history, and hence frailty of these clients, is less well-
known to other-source prescribers than by GPs.
4.3. Strengths and limitations of this study
First, Scotland has a national protocol for toxicological testing
at forensic autopsy which underpins the opioid-speciﬁcity of its
DRDs. Secondly, unparalleled for a national cohort (Sullivan et al.,
2014), we could analyse the quantity of methadone prescribed at
cohort-entry in addition to demographic risks for a large cohort of
33,000 methadone-clients who  experienced 760 recent-past DRDs,
362 of them methadone-speciﬁc DRDs.
Third, to minimize ascertainment bias, we  considered only the
baseline (not time-varying) quantity of methadone prescribed at
the ﬁrst CHI-identiﬁed methadone prescription. This ﬁrst CHI-
identiﬁed prescription deﬁned the client’s entry to Scotland’s
methadone-client cohort (2009–2013) but was  typically not the
client’s ﬁrst methadone prescription, especially if cohort-entry
was in 2009. We  therefore investigated covariate inﬂuences on
methadone-speciﬁc DRDs separately for mostly prevalent clients
versus those accrued after 2009 whose baseline quantity of pre-
scribed methadone may  have been pre-stabilization. Besides a
differential association with other-source prescribing, we found
that two other hazards for methadone-speciﬁc DRD were more
extreme for the mostly incident than for mostly prevalent clients:
aged 45+ years and highest quintile for quantity prescribed. Both
underscore our main ﬁndings.
Turning to limitations, of which there are several, we  acknowl-
edge ﬁrst that only 63% of all methadone prescriptions during
2009/10 to 2012/13 were CHI-identiﬁed. However, our 33,128 CHI-
identiﬁed methadone clients represented, at a best estimate, 82% of
Scotland’s methadone-clients over the four years (plausible range:
70% to 93%), a more critical measure of completeness being client-
based.
The unavailability of daily-dose for other-source prescriptions
and for half of the ﬁrst CHI-identiﬁed prescriptions by GPs  is, of
course, regrettable: and especially so as our analysis in Supplemen-
tary material6 for the GP-subset suggested that the highest quintile
6 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org and by entering doi:. . .
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or daily prescribed methadone was more prognostic even than
he quantity prescribed. Irrespective of whether daily-dose was
vailable or not, summary statistics on the number of prescription-
nstalments by GPs were reassuringly similar so that any bias in
he GP-subset may  be more apparent than real. Nonetheless, we’d
ave preferred that daily-dose at ﬁrst CHI-identiﬁed prescription
ad been accessible electronically for 80% or more clients.
The need to substitute, for missing ﬁrst prescription-date, the
ater reimbursement-date was a minor issue. More importantly,
e did not know, and hence could not analyse (Cornish et al.,
010; Pierce et al., 2015a; Cousins et al., 2016), when clients exited
rom methadone therapy as the date of their last CHI-identiﬁed
ethadone-prescription does not exclude later non-CHI prescrip-
ions. Hence, once included in the cohort, clients have remained in
ollow-up.
A ﬁfth limitation, in common with most unconsented record-
inkage studies, is that we had little scope for resolving
ata-queries, such as some apparent inconsistencies (2%) between
uantity of methadone prescribed and daily-dose.
Benzodiazepines (licit or illicit), alcohol and methadone con-
pire in terms of DRD-risk (Merrall et al., 2012; Pierce et al., 2015a,
016), as evidenced by their co-presence at DRDs (Bird et al.,
010; Bird and Robertson, 2011; Barnsdale et al., 2015, 2016)
nd by the co-prescription of benzodiazepines with opioids for
ain (Christie, 2011; Leece et al., 2015; Park et al., 2015). We  did
ot request that methadone clients’ co-prescriptions for benzo-
iazepines be linked-in because the added time and complexity
ould not have been warranted given that illicit supplies would
emain unaccounted for and, among Scotland’s DRDs, are the sub-
tantial majority (Barnsdale et al., 2015, 2016).
Seventh, association is not causation (Hill, 1965): age over
5 years and higher quantity of methadone prescribed may
e respectively demographic and pharmacological markers for
arder-to-support clients whose opioid dependency is chronic and
ikewise their HCV progression (Eap et al., 2002). Research into
ender differences in opioid analgesia and addiction has given con-
icting results (Lee and Ho, 2013; Graziani and Nistico, 2015; Bawor
t al., 2014) but being female is a risk-factor for QTc prolongation
Makkar et al., 1993), which may  partly explain why, for females,
he risk of methadone-speciﬁc DRDs is not lower than for their male
ounterparts.
. Conclusions
Vindicating our hypothesis, Scotland’s methadone-prescription
ohort has revealed high methadone-speciﬁc DRD rates in older
lients irrespective of gender; and increased hazard for the
op quintile of prescribed methadone. Better understanding is
eeded of the pharmaco-dynamics of methadone for older, opioid-
ependent clients, many with progressive liver, cardiovascular or
ther disease.
Guidelines on the prescribing of methadone in the UK will
e updated in 2016. The Scottish data signal that methadone-
rescribers and other specialists should exercise particular caution
n managing older clients, many of whom are HCV-infected or
lcohol-dependent; and if their daily-dose of methadone exceeds
0 mg  or the quantity of methadone per prescription exceeds
960 mg.
Higher methadone-speciﬁc DRD-rate for older clients, and thebsence of a gender differential, should be noted by prescribers and
y clients themselves. We  recommend that take-home naloxone
e prescribed for methadone-clients (Strang et al., 2014; Bird et al.,
015, 2016), especially those aged 35+ years.ndence 167 (2016) 214–223 221
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